Apella Capital LLC Purchases Shares of 2,973 Tenet Healthcare Corporation $THC

Apella Capital LLC acquired a new position in Tenet Healthcare Corporation (NYSE:THC) during the first quarter, HoldingsChannel.com reports. The fund acquired 2,973 shares of the company’s stock, valued at approximately $585,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of THC. NewEdge Advisors LLC grew its stake in Tenet Healthcare by 6.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,890 shares of the company’s stock worth $389,000 after buying an additional 166 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Tenet Healthcare by 299.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company’s stock valued at $229,000 after purchasing an additional 1,274 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Tenet Healthcare during the second quarter worth $290,000. Quantbot Technologies LP purchased a new stake in shares of Tenet Healthcare during the second quarter valued at $65,000. Finally, Amundi increased its position in shares of Tenet Healthcare by 4,207.8% in the 2nd quarter. Amundi now owns 27,010 shares of the company’s stock valued at $4,652,000 after acquiring an additional 26,383 shares during the period. Hedge funds and other institutional investors own 95.44% of the company’s stock.

Tenet Healthcare Stock Up 2.0%

Shares of THC opened at $187.64 on Friday. The company has a market capitalization of $16.16 billion, a price-to-earnings ratio of 9.76, a PEG ratio of 1.56 and a beta of 1.28. Tenet Healthcare Corporation has a 52 week low of $146.60 and a 52 week high of $247.21. The stock’s 50-day moving average price is $181.14 and its 200-day moving average price is $197.51. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The company had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.39 billion. During the same period last year, the business earned $4.36 earnings per share. Tenet Healthcare’s quarterly revenue was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, sell-side analysts predict that Tenet Healthcare Corporation will post 17.61 EPS for the current year.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, Director J Robert Kerrey sold 5,638 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $174.52, for a total value of $983,943.76. Following the completion of the transaction, the director owned 16,804 shares in the company, valued at approximately $2,932,634.08. This represents a 25.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total value of $532,050.00. Following the sale, the director owned 24,805 shares in the company, valued at $4,399,166.75. This trade represents a 10.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on THC shares. Mizuho boosted their price target on Tenet Healthcare from $235.00 to $265.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tenet Healthcare in a report on Wednesday, March 4th. Guggenheim dropped their target price on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Robert W. Baird reduced their price target on shares of Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. Finally, Barclays decreased their price objective on shares of Tenet Healthcare from $257.00 to $238.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Eighteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $244.32.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.